CryoLife - AORT Net earnings per one share for the last twelve months

Proprietary manufacturing plants in Europe and the US guarantee supply stability, as evidenced by the 12-month annual EPS growth trend. The business's resilience to crises and strict adherence to cryogenic transport regulations minimize operational disruptions. The value of -51.90 reflects the latest metric level, allowing for a real-time assessment of Artivion, Inc. (AORT) efficiency within the specialized medical equipment sector.
CryoLife - analytical breakdowns and key metrics (AORT)

The assessment of Artivion, Inc. (AORT) margin of safety is based on an analysis of earnings per share growth rates, which measure the business capitalization efficiency relative to the previous year. The current value of -51.90 regarding historical EPS YoY growth over the last 12 months reflects the company's ability to monetize developments in cardiac surgical implants and stent grafts, determining the justification for the market control premium.